N. Bartlett

发表

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.

M. Grever, J. Byrd, J. Gribben, 2005, Leukemia research.

Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma

R. Levy, J. Friedberg, I. Flinn, 2017, The New England journal of medicine.

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

L. Gordon, M. Czuczman, F. Cabanillas, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma

N. Bartlett, K. Foyil, 2012, Cancer journal.

Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.

Christopher A. Miller, Matthew K. Matlock, L. Trani, 2017, Blood.

Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).

J. Friedberg, C. Flowers, J. Hainsworth, 2015, Blood.

Therapy in primary mediastinal B-cell lymphoma.

B. Christian, N. Bartlett, A. Cashen, 2013, The New England journal of medicine.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

A. Zelenetz, J. Friedberg, B. Cheson, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

R. Houot, J. Briones, C. Flowers, 2021, Leukemia & lymphoma.

Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CALGB 50904 (Alliance)

J. Leonard, B. Cheson, Sin-Ho Jung, 2019, Cancer.

Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma

Roland Schmitz, Bao Tran, Yongmei Zhao, 2018, The New England journal of medicine.

Brentuximab vedotin for the treatment of CD30+ lymphomas.

N. Bartlett, K. Foyil, 2011, Immunotherapy.

Biologic agents in the management of Hodgkin lymphoma.

N. Bartlett, A. Rashidi, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Non-Hodgkin's lymphomas, version 4.2014.

J. Byrd, R. Advani, J. Vose, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

SGN-30 (Anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)

J. Leonard, B. Cheson, C. Haioun, 2004 .

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

J. Friedberg, J. Leonard, B. Cheson, 2015 .

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

D. Miklos, C. Jacobson, N. Bartlett, 2017, Blood.

18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation

Andrew Homb, Jingqin Luo, B. Siegel, 2011, The Journal of Nuclear Medicine.

CAR‐T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder

N. Bartlett, A. Ghobadi, J. Schilling, 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.

F. Gao, F. Gao, J. Dipersio, 2020, Blood.

Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.

Angelique Zeringue, Kenneth R Carson, Jingxia Liu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

R. Gascoyne, L. Gordon, R. Fisher, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

M. Hallek, A. Chanan-Khan, A. Howes, 2016, The Lancet. Oncology.

SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma

N. Bartlett, M. Fanale, Marcus P. Watkins, 2018, Clinical lymphoma, myeloma & leukemia.

Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.

N. Bartlett, N. Mehta-Shah, 2018, Blood.

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.

N. Bartlett, 2017, Hematology. American Society of Hematology. Education Program.

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

T. Kipps, Carol Moreno, N. Bartlett, 2018, Haematologica.

Assessment of knowledge about cancer pain management by physicians in training.

N. Bartlett, J. Mortimer, 1997, Journal of pain and symptom management.

Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.

Y. Natkunam, S. Horning, S. Horwitz, 2003, Blood.

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.

R. Advani, A. Evens, N. Bartlett, 2021, Blood advances.

Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials

J. Crawford, B. Peterson, N. Bartlett, 2002, Cancer.

Barriers to clinical trial participation by older women with breast cancer.

H. Cohen, B. Peterson, N. Bartlett, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Barriers t o C linical T rial P articipation b y O lder W omen W ith Breast C ancer

H. Cohen, B. Peterson, N. Bartlett, 2003 .

Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Vanessa R. Sanders, J. Ippolito, D. Ludwig, 2022, Cancers.

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma.

Sonali M. Smith, A. LaCasce, J. Friedberg, 2019, Blood.

CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma

N. Bartlett, A. Ghobadi, 2021, The Lancet.

Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial.

W. Wilson, A. Zelenetz, J. Friedberg, 2020, Blood.

Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.

R. Advani, B. Cheson, A. Evens, 2021, Clinical lymphoma, myeloma & leukemia.

A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.

D. Northfelt, N. Bartlett, J. Drachman, 2009 .

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2021, Blood advances.

Blinatumomab for the treatment of B-cell lymphoma

N. Bartlett, Eunhye Oak, 2015, Expert opinion on investigational drugs.

The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas

D. Piwnica-Worms, N. Bartlett, H. Wong, 2015, Clinical Cancer Research.

Management of Classical Hodgkin Lymphoma

N. Bartlett, K. Sanfilippo, 2014 .

Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy.

N. Bartlett, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.

R. Bociek, J. Leonard, A. Younes, 2008, Blood.

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

Sonali M. Smith, B. Cheson, Sin-Ho Jung, 2013, Leukemia & lymphoma.

Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.

Andrew Homb, R. Vij, P. Westervelt, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Therapy of relapsed Hodgkin lymphoma.

N. Bartlett, A. Cashen, 2007, Blood reviews.

Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.

N. Bartlett, 2005, Hematology. American Society of Hematology. Education Program.

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206

B. Cheson, D. Niedzwiecki, K. Blum, 2007, Leukemia & lymphoma.

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis

R. Advani, R. Gascoyne, Sonali M. Smith, 2018, Cancer.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

John P Leonard, J. Leonard, A. Younes, 2010, The New England journal of medicine.

A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma

N. Bartlett, Eunhye Oak, 2016, Expert opinion on drug safety.

Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary.

Tudung T Nguyen, N. Bartlett, F. Kreisel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?

N. Bartlett, S. Goyal, 2012, Current Hematologic Malignancy Reports.

Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

N. Bartlett, K. Foyil, A. Cashen, 2012, Leukemia & lymphoma.

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

K. Savage, F. Morschhauser, L. Trümper, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Craig B. Davis, R. Houot, X. Mu, 2020, Clinical Cancer Research.

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular andOther CD20þNon-Hodgkin Lymphomas

Craig B. Davis, R. Houot, X. Mu, 2020 .

Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.

R. Advani, J. Connors, K. Savage, 2019, Blood.

A Prospective Multicenter Phase 2 Study of Dose-Adjusted-EPOCH-R in Untreated MYC-Rearranged Aggressive B-cell Lymphoma

W. Wilson, S. Steinberg, J. Friedberg, 2019 .

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.

G. Salles, K. Kolibaba, H. Tilly, 2019, The Lancet. Oncology.

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.

R. Advani, S. Horwitz, T. Illidge, 2018, Blood.

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.

O. Griffith, M. Griffith, B. Costello, 2018, Blood.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

J. Connors, K. Savage, Y. Oki, 2017, The New England journal of medicine.

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Scott E. Smith, Sonali M. Smith, J. Leonard, 2017, The Lancet. Haematology.

A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma

K. Blum, M. Phelps, B. Christian, 2017, Clinical lymphoma, myeloma & leukemia.

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

R. Advani, J. Connors, T. Illidge, 2017, Blood.

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma

N. Bartlett, P. Brice, M. Fanale, 2016, OncoTargets and therapy.

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies

Scott E. Smith, N. Bartlett, O. O’Connor, 2015, Leukemia & lymphoma.

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial

R. Advani, B. Coiffier, S. Ansell, 2015, Leukemia & lymphoma.

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

R. Advani, S. Horwitz, T. Illidge, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Scott E. Smith, R. Advani, N. Bartlett, 2014, Journal of Hematology & Oncology.

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphoma

J. Vose, B. Cheson, N. Bartlett, 2012, Cancer.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

D. Fisher, S. Horwitz, N. Bartlett, 2012, Blood.

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.

J. Byrd, B. Cheson, Sin-Ho Jung, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies

P. Fracasso, K. Blum, N. Bartlett, 2002, Cancer.

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

I. Lossos, J. Friedberg, J. Leonard, 2022, Blood advances.

Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle.

N. Bartlett, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation

D. Dunn, N. Bartlett, V. Morrison, 2005, Cancer.

Antibodies for the treatment of diffuse large cell lymphoma.

K. Blum, N. Bartlett, 2003, Seminars in oncology.

Primary gastric plasmacytoma: a rare cause of hypertrophic gastritis in an adolescent.

N. Bartlett, A. Goyal, J. Langer, 1999, Journal of pediatric gastroenterology and nutrition.

Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496

R. Advani, R. Gascoyne, L. Gordon, 2010 .

Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin’s Disease (NLPHD).

R. Advani, S. Horning, N. Bartlett, 2007 .

Dose‐escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma

G. Petroni, B. Parker, N. Bartlett, 2001, Cancer.

Prognostic factors in inflammatory breast cancer. Univariate and multivariate analysis

C. Perez, N. Bartlett, R. Kuske, 1989, Cancer.

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

R. Advani, R. Gascoyne, L. Gordon, 2013, Blood.

Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.

J. Leonard, Ying Yuan, N. Bartlett, 2021, The Lancet. Haematology.

Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.

B. Cheson, S. Ansell, B. Christian, 2020, The Lancet. Haematology.

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.

A. LaCasce, A. Freedman, P. Armand, 2020, Blood advances.

Non-Hodgkin's Lymphomas, version 3.2012.

J. Byrd, R. Advani, J. Vose, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602.

Sonali M. Smith, B. Cheson, Sin-Ho Jung, 2010 .

Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202

Sonali M. Smith, J. Leonard, B. Cheson, 2014 .

Solid, low-attenuation splenic lesions on computed tomography in patients with indolent lymphoma often signal transformation: a series of ten patients.

J. Welch, N. Bartlett, W. Middleton, 2012, Clinical lymphoma, myeloma & leukemia.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Scott E. Smith, Allison M. Booth, J. Byrd, 2018, The New England journal of medicine.

Composite diffuse large B-cell lymphoma and precursor B lymphoblastic lymphoma presenting as a double-hit lymphoma with MYC and BCL2 translocation

Tudung T Nguyen, S. Nanua, N. Bartlett, 2011, Journal of Clinical Pathology.

Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.

D. Brat, M. Mehta, B. Fisher, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)

A. LaCasce, A. Ruppert, N. Bartlett, 2021, Hematological Oncology.

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

R. Advani, J. Connors, K. Savage, 2021, The Lancet. Haematology.

CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).

A. LaCasce, J. Leonard, B. Cheson, 2021 .

Non-Hodgkin's lymphomas, version 2.2014.

J. Byrd, R. Advani, J. Vose, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: A teaching case.

S. Mutic, N. Bartlett, Y. Rao, 2017, Practical radiation oncology.

A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma

N. Bartlett, Marcus P. Watkins, Marcus P Watkins, 2020, Leukemia & lymphoma.

Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816

Sonali M. Smith, J. Friedberg, J. Leonard, 2020, Leukemia & lymphoma.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, New England Journal of Medicine.

Fine-Tuning the Treatment of Hodgkin's Lymphoma.

N. Bartlett, 2016, The New England journal of medicine.

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

L. Sehn, I. Flinn, N. Bartlett, 2018, Blood.

Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.

R. Advani, Sonali M. Smith, I. Flinn, 2018 .

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2014 .

Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.

B. Coiffier, C. Haioun, S. Horwitz, 2012, Clinical lymphoma, myeloma & leukemia.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

J. Byrd, R. Advani, J. Vose, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Non-Hodgkin’s Lymphomas, Version 4.2014: Clinical Practice Guidelines in Oncology

J. Byrd, R. Advani, J. Vose, 2014 .

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

J. Byrd, R. Advani, J. Vose, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

M. Czuczman, J. Leonard, B. Cheson, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

Y. Natkunam, R. Advani, S. Horning, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma

M. Czuczman, J. Leonard, B. Cheson, 2009, Cancer.

Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.

L. Gordon, J. Murray, N. Bartlett, 2004, Cancer biotherapy & radiopharmaceuticals.

Bone marrow staging in patients with non‐hodgkin's lymphoma

M. Naughton, N. Bartlett, M. Zutter, 1998, Cancer.

Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study

J. Dipersio, N. Bartlett, T. Fehniger, 2018, Leukemia & lymphoma.

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.

J. Leonard, C. Flowers, T. Habermann, 2020, The Lancet. Haematology.

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in CALGB 50401 (Alliance)

J. Leonard, C. Flowers, T. Habermann, 2020 .

Randomized, double-blind, phase 2, study evaluating same-day vs next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients.

A. Saven, N. Bartlett, L. Schwartzberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma

J. Leonard, N. Bartlett, A. Forero-Torres, 2008 .

90Yttrium–ibritumomab tiuxetan: a novel treatment for non-Hodgkin’s lymphoma

K. Blum, N. Bartlett, 2004, Expert opinion on biological therapy.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

D. Scott, Sonali M. Smith, J. Friedberg, 2019, Blood.

Non-Hodgkin's lymphomas, version 1.2013.

J. Byrd, R. Advani, J. Vose, 2013, The Journal of the National Comprehensive Cancer Network.

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

R. Advani, S. Horwitz, T. Illidge, 2013 .

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2013 .

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.

R. Advani, Y. Oki, S. Horwitz, 2012 .

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

L. Sehn, S. Dietrich, N. Bartlett, 2021, Blood.

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

A. Salar, E. W. Van Den Neste, N. Bartlett, 2021, Blood.

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines.

L. Sehn, F. Bosch, K. Yousefi, 2019, Blood.

A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496)

R. Advani, R. Gascoyne, L. Gordon, 2010 .

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

R. Advani, J. Vose, L. Gordon, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial

R. Gascoyne, D. Scott, L. Gordon, 2011 .

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Scott E. Smith, R. Advani, N. Bartlett, 2011 .

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.

I. Lossos, R. Advani, J. Vose, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Scott E Smith, Bruce D Cheson, Andreas Engert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress.

N. Bartlett, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

R. Advani, J. Connors, J. Friedberg, 2022, The New England journal of medicine.

Transformed Follicular Lymphoma: Is Early Autologous Stem Cell Transplantation Indicated in the Modern Era?

N. Bartlett, A. Cashen, Jingxia Liu, 2014 .

Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.

N. Bartlett, A. Rashidi, Eunhye Oak, 2015, Blood.

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

G. Salles, K. Kolibaba, H. Tilly, 2016 .

Intravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature.

N. Bartlett, D. Jones, M. Kraus, 1999, The American journal of medicine.

Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)

A. LaCasce, J. Leonard, B. Cheson, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

R. Advani, J. Connors, T. Illidge, 2011 .

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

L. Staudt, W. Wilson, S. Steinberg, 2014 .

Cyclin D1 as an Aid in the Diagnosis of Mantle Cell Lymphoma in Skin Biopsies: A Case Report

N. Bartlett, M. Kraus, B. Moody, 2001, The American Journal of dermatopathology.

Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas.

J. Leonard, A. Younes, N. Bartlett, 2008 .

HIGH PROLIFERATION (MCL35 ASSAY) IS ASSOCIATED WITH INFERIOR OUTCOMES IN PATIENTS TREATED WITH INTENSIVE REGIMENS—A CORRELATIVE STUDY FROM THE CALGB 50403 (ALLIANCE) TRIAL

D. Scott, J. Leonard, A. Mottok, 2017 .

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

L. Sehn, I. Flinn, L. Xerri, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protect our children: Hodgkin lymphoma survivors.

N. Bartlett, 2021, Blood.

Radiation for early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a double-edged sword?

N. Bartlett, A. Rashidi, 2016, Leukemia & lymphoma.

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

R. Advani, J. Connors, J. Radford, 2018, Blood.

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Sonali M. Smith, J. Friedberg, J. Leonard, 2017 .

THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL

R. Gascoyne, D. Scott, J. Friedberg, 2017 .

Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin

N. Bartlett, J. Berger, A. Cashen, 2012, Leukemia & lymphoma.

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

L. Sehn, F. Bosch, I. Flinn, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

W. Wilson, Y. Oki, F. Turturro, 2018, Haematologica.

Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

A. LaCasce, K. Savage, P. Zinzani, 2018, Journal of Clinical Oncology.

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Sonali M. Smith, A. LaCasce, J. Friedberg, 2018, Blood.

Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL)

N. Bartlett, F. Dehdashti, A. Cashen, 2008 .

Stem cell transplant for lymphoma - never too late?

N. Bartlett, A. Cashen, 2022, Haematologica.

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2016 .

The justification of vincristine dose capping: tradition, tradition…tradition!

N. Bartlett, 2020, Leukemia & lymphoma.

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

J. Vose, M. Kersten, C. Jacobson, 2021, Blood.

Phase II Study of Thalidomide in Escalating Doses for Follicular (F-NHL) and Small Lymphocytic Lymphoma (Sll): CALGB Study 50002.

B. Cheson, N. Bartlett, D. Rizzieri, 2004 .

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2010 .

Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome.

L. Wartman, N. Bartlett, E. Duncavage, 2019, Clinical lymphoma, myeloma & leukemia.

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

M. Hallek, A. Chanan-Khan, A. Howes, 2020, Leukemia & lymphoma.

Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

S. M. Lavezzi, G. Nicolao, A. Howes, 2019, Pharmaceutical Research.

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

M. Hallek, A. Chanan-Khan, A. Howes, 2018, Leukemia.

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

J. Byrd, R. Advani, J. Vose, 2017 .

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

J. Byrd, R. Advani, J. Vose, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206.

B. Cheson, D. Niedzwiecki, K. Blum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation.

M. Fleming, D. Dorfman, N. Bartlett, 1998, The American journal of surgical pathology.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas

R. Advani, S. Horwitz, T. Illidge, 2012 .

Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphoma

A. LaCasce, J. Friedberg, J. Leonard, 2017, British journal of haematology.

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

F. Awan, D. Weiner, B. Christian, 2022, Journal of Hematology & Oncology.

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

W. Wilson, S. Steinberg, P. Bierman, 2015 .

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

T. Kipps, G. Gaidano, A. Schuh, 2015, The New England journal of medicine.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

R. Advani, J. Briones, G. Salles, 2019, The Lancet.

A Young Woman With Blurred Vision and Distal Paresthesias.

N. Bartlett, N. Kung, G. Van Stavern, 2015, JAMA neurology.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

W. Wilson, S. Steinberg, A. LaCasce, 2018, The Lancet. Haematology.

CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma

I. Weissman, R. Advani, Sonali M. Smith, 2018, The New England journal of medicine.

Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines

J. Byrd, R. Advani, J. Vose, 2012 .

PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

B. Coiffier, S. Horwitz, N. Bartlett, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.

R. Advani, R. Gascoyne, D. Scott, 2012, Blood.

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

N. Bartlett, J. Rossi, S. Neelapu, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Chimeric Antigen Receptor T-Cell Therapy.

R. Carlson, E. Shpall, T. Fry, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

I. Flinn, D. Miklos, C. Jacobson, 2019, The Lancet. Oncology.

Serum markers in germ cell neoplasms.

F. Freiha, F. Torti, N. Bartlett, 1991, Hematology/Oncology Clinics of North America.

Non-Hodgkin's lymphomas, version 1.2013.

J. Byrd, R. Advani, J. Vose, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis

N. Bartlett, K. Carson, N. Wagner-Johnston, 2014, Leukemia & lymphoma.

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

B. Sikic, N. Bartlett, G. Fisher, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

R. Advani, J. Winter, Y. Oki, 2015, Blood.

Hodgkin lymphoma

J. Connors, C. Steidl, N. Bartlett, 2020, Nature Reviews Disease Primers.

Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

Joshua F. McMichael, Zachary L. Skidmore, Christopher A. Miller, 2021, medRxiv.

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

Erica K. Barnell, Zachary L. Skidmore, R. Fulton, 2022, medRxiv.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

K. Savage, B. Coiffier, C. Gisselbrecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study

Michael L. Wang, M. Kaminski, J. Winter, 2014, British journal of haematology.

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma

Ying Luan, J. Vose, L. Gordon, 2015, Clinical Cancer Research.

Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

Ryan D. Morin, Nicholas B. Griner, L. Staudt, 2021, medRxiv.

AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1

D. Miklos, C. Jacobson, N. Bartlett, 2017 .

Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551

M. Ratain, N. Bartlett, B. Peterson, 2009, Cancer Chemotherapy and Pharmacology.

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Scott E. Smith, Allison M. Booth, J. Byrd, 2018, Blood.

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.

R. Advani, J. Vose, A. LaCasce, 2018, Blood.

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).

R. Advani, R. Gascoyne, L. Gordon, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphomas Presenting in the Head and Neck

N. Bartlett, 2010 .

Formulating a Treatment Plan in Suspected Lymphoma: Ultrasound‐Guided Core Needle Biopsy Versus Core Needle Biopsy and Fine‐Needle Aspiration of Peripheral Lymph Nodes

M. Yano, Michael F. Lin, N. Bartlett, 2018, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

R. Gascoyne, A. LaCasce, J. Friedberg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

R. Advani, R. Gascoyne, L. Gordon, 2013, British journal of haematology.

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

Ash A. Alizadeh, R. Tibshirani, J. Vose, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LYMPHOMA OF THE MEDIASTINUM

N. Bartlett, T. Fenske, 2008 .

Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma

F. Gao, Richard J. Jones, N. Bartlett, 2021, Leukemia & lymphoma.

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

J. Connors, J. Friedberg, J. Leonard, 2017, Journal of the National Cancer Institute.

Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906

Sonali M. Smith, B. Cheson, D. Niedzwiecki, 2006, Leukemia & lymphoma.

Treatment advances in non-Hodgkin’s lymphoma

N. Bartlett, B. Tan, 2000, Expert opinion on pharmacotherapy.

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

R. Advani, N. Bartlett, A. Forero-Torres, 2011, Clinical Cancer Research.

Management of advanced stage Hodgkin's lymphoma.

N. Bartlett, A. J. Smukler, 2006, Cancer treatment and research.

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.

I. Lossos, P. Armand, L. Alland, 2020, Blood.

Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers

N. Bartlett, F. Kreisel, K. Foyil, 2014, Therapeutic advances in hematology.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

G. Salles, L. Sehn, A. López-Guillermo, 2018, The New England journal of medicine.

Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.

R. Advani, J. Vose, Sonali M. Smith, 2021, Clinical lymphoma, myeloma & leukemia.

Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.

R. Advani, J. Vose, Sonali M. Smith, 2021, Clinical lymphoma, myeloma & leukemia.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

R. Advani, L. Gordon, J. Connors, 2019, Clinical Cancer Research.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

R. Advani, J. Connors, T. Illidge, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

J. Leonard, A. Younes, N. Bartlett, 2009, British journal of haematology.

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

B. Cheson, Sin-Ho Jung, A. Freedman, 2011, Leukemia & lymphoma.

Inflammatory carcinoma of the breast: treatment results on 107 patients.

C. Perez, N. Bartlett, R. Kuske, 1989, International journal of radiation oncology, biology, physics.

PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy

O. Elemento, J. Leonard, L. Cantley, 2016 .

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

W. Wilson, S. Steinberg, P. Bierman, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

L. Gordon, J. Friedberg, R. Coffman, 2018, Cancer discovery.

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.

R. Advani, J. Vose, A. LaCasce, 2021, Blood.

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

R. Advani, J. Vose, A. LaCasce, 2019, Blood.

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.

K. Trinkaus, K. Blum, N. Bartlett, 2011, Blood.

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

R. Advani, Y. Oki, S. Horwitz, 2014, Blood.

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.

Sonali M. Smith, J. Friedberg, J. Leonard, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.

Scott E. Smith, Sonali M. Smith, M. Czuczman, 2015, Blood.

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.

R. Advani, J. Vose, L. Gordon, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma

N. Bartlett, Marcus P Watkins, M. Malecek, 2020, Expert opinion on biological therapy.

HEMATOLOGIC MALIGNANCIES : LYMPHOMA

N. Bartlett, N. Wagner-Johnston, 2007 .

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

J. Leonard, B. Cheson, B. Pitcher, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.

S. Horning, B. W. Brown, N. Bartlett, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follicular large-cell lymphoma: intermediate or low grade?

S. Horning, J. Halpern, N. Bartlett, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

J. Byrd, A. LaCasce, B. Cheson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma

N. Bartlett, A. Goy, R. Ramchandren, 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Sonali M. Smith, J. Friedberg, C. Flowers, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

L. Gordon, J. Murray, N. Bartlett, 2002, Blood.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

J. Friedberg, J. Leonard, B. Cheson, 2018, Blood.

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.

A. LaCasce, L. Schwartz, B. Cheson, 2011, Blood.

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.

J. Leonard, S. Chen‐Kiang, G. Inghirami, 2019, Blood.

Interim [ 18 F ] fl uorodeoxyglucose positron emission tomography imaging in stage I – II non-bulky Hodgkin lymphoma : would using combined positron emission tomography and computed tomography criteria better predict response than each test alone ?

A. LaCasce, L. Schwartz, B. Cheson, 2012 .

Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted EPOCH‐R

Sonali M. Smith, A. LaCasce, J. Leonard, 2017, British journal of haematology.

Immunohistochemi-NCCN Diffuse Large B-Cell Lymphoma Version 1 . 2016 Clinical Practice Guidelines in Oncology

J. Byrd, R. Advani, J. Vose, 2016 .

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

T. Kipps, N. Bartlett, J. Burger, 2016 .

Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.

M. Hallek, A. Howes, N. Bartlett, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

Scott E. Smith, Allison M. Booth, J. Byrd, 2021, Leukemia.

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

A. LaCasce, J. Friedberg, I. Flinn, 2016, European journal of cancer.

A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.

R. Advani, J. Winter, B. Cheson, 2008 .

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

L. Staudt, W. Wilson, A. Zelenetz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Bruce D Cheson, R. Advani, J. Winter, 2014, Journal of Hematology & Oncology.

A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.

Craig B. Davis, H. Kohrt, R. Houot, 2014 .

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

J. Friedberg, I. Flinn, D. Miklos, 2016 .

THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

A. LaCasce, I. Flinn, N. Bartlett, 2019, Hematological Oncology.

CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas

N. Bartlett, Marcus P. Watkins, Marcus P Watkins, 2018, Expert opinion on investigational drugs.

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

I. Flinn, M. Maris, M. Davids, 2022, Blood.

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.

D. Miklos, C. Jacobson, N. Bartlett, 2020, Blood.

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

J. Vose, M. Kersten, C. Jacobson, 2021, British journal of haematology.

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.

S. Hancock, S. Horning, S. Rosenberg, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome

Tudung T Nguyen, N. Bartlett, F. Kreisel, 2016, Applied immunohistochemistry & molecular morphology : AIMM.

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

J. Zaucha, N. Bartlett, T. Phillips, 2021, Blood.

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

J. Zaucha, N. Bartlett, T. Phillips, 2022, Blood.

Anti-CD30 Antibodies for Hodgkin Lymphoma

N. Bartlett, K. Foyil, 2010, Current hematologic malignancy reports.

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Jeffrey A Jones, Sonali M. Smith, A. LaCasce, 2021, Blood.

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.

L. Sehn, S. Dietrich, N. Bartlett, 2022, The Lancet. Oncology.

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

O. Griffith, F. Gao, M. Griffith, 2021, Clinical Cancer Research.

Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience.

K. Trinkaus, N. Bartlett, T. Johanns, 2019, Clinical lymphoma, myeloma & leukemia.

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

P. Zinzani, N. Bartlett, J. Kuruvilla, 2022, Leukemia & lymphoma.

Drug development for recurrent and refractory classical Hodgkin lymphoma

N. Bartlett, T. Wildes, 2009, Leukemia & lymphoma.

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

L. Gordon, M. Czuczman, N. Bartlett, 2004, Clinical lymphoma.

A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory classical Hodgkin lymphoma.

J. Dipersio, N. Bartlett, C. Abboud, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Progressive multifocal leukoencephalopathy treated with nivolumab

D. Clifford, N. Bartlett, Manu Goyal, 2019, Journal of NeuroVirology.

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

J A Parker, W D Erwin, D. Podoloff, 2001, Critical reviews in oncology/hematology.

Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492.

D. Neuberg, S. Horning, J. Bennett, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2019, Blood.

Salvage regimens for Hodgkin lymphoma.

N. Bartlett, A. Cashen, 2008, Clinical advances in hematology & oncology : H&O.

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Scott E. Smith, J. Friedberg, A. Younes, 2014, Leukemia & lymphoma.

A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL)

K. Blum, B. Christian, N. Bartlett, 2012 .

Progressive multifocal leukoencephalopathy treated with nivolumab

R. Schmidt, D. Clifford, N. Bartlett, 2019, Journal of NeuroVirology.

Lymphoma Surveillance Counterpoint: USA

N. Bartlett, K. Carson, 2013 .

Thalidomide has limited single‐agent activity in relapsed or refractory indolent non‐Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B

Sonali M. Smith, B. Cheson, D. Niedzwiecki, 2008, British journal of haematology.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

J. Leonard, B. Cheson, B. Pitcher, 2017 .

A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results

K. Trinkaus, J. Dipersio, K. Blum, 2008 .

Targeting CD30 as therapy for Hodgkin's disease. Phase II results with the monoclonal antibody SGN-30

J. Leonard, A. Younes, N. Bartlett, 2005 .

MACOP‐B ± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices

S. Horning, L. Kwak, N. Bartlett, 1993, Cancer.

Hodgkin’s disease: Prognostic factors and short-course regimens

N. Bartlett, Sophia M. Arackal, Sophia M. Arackal, 2000, Current oncology reports.

Diffuse Large B-Cell Lymphoma Version 1.2016.

J. Byrd, R. Advani, J. Vose, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403

J. Byrd, D. Scott, A. LaCasce, 2020, American journal of hematology.

CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma.

Tudung T Nguyen, N. Bartlett, F. Kreisel, 2014, American journal of clinical pathology.

Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.

G. Colditz, P. Riedell, C. Nabhan, 2015, Journal of geriatric oncology.

Approaches to aggressive B-cell lymphomas in less fit patients.

N. Bartlett, 2020, Hematology. American Society of Hematology. Education Program.

CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.

J. Leonard, B. Cheson, Sin-Ho Jung, 2014 .

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

L. Sehn, N. Bartlett, M. Wei, 2020 .

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

Scott E. Smith, M. Czuczman, J. Leonard, 2018, Cancer medicine.

INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

J. Vose, A. LaCasce, S. Ansell, 2017 .

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

B. Siegel, C. Erlichman, N. Bartlett, 2014 .

Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria

N. Bartlett, A. Rashidi, F. Kreisel, 2016, Leukemia & lymphoma.

Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance)

Scott E. Smith, M. Czuczman, J. Leonard, 2016 .

Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.

M. Czuczman, J. Leonard, B. Cheson, 2020, The American journal of surgical pathology.

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

R. Advani, K. Savage, Y. Oki, 2017, Leukemia & lymphoma.

Role of routine imaging in lymphoma.

N. Bartlett, N. Wagner-Johnston, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era

R. Advani, R. Gascoyne, L. Gordon, 2015, British journal of haematology.

Phase 2 multicentre study of single‐agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)

Sonali M. Smith, J. Leonard, B. Cheson, 2019, British journal of haematology.

Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

H. Cohen, J. Byrd, J. Leonard, 2018, Journal of geriatric oncology.

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

G. Salles, L. Sehn, A. López-Guillermo, 2019, Blood.

Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma.

N. Bartlett, L. Nastoupil, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort

Sonali M. Smith, J. Friedberg, J. Leonard, 2018, Haematologica.

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

R. Advani, R. Gascoyne, L. Gordon, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials

J. Friedberg, J. Leonard, B. Cheson, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.

C. Jacobson, N. Bartlett, L. Lekakis, 2020 .

Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).

D. Miklos, J. Galon, J. Rossi, 2017 .

Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).

L. Sehn, F. Bosch, I. Flinn, 2019, Journal of Clinical Oncology.

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

D. Northfelt, N. Bartlett, A. Lobuglio, 2013, Leukemia & lymphoma.

S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY

J. Connors, K. Savage, J. Radford, 2019, HemaSphere.

Assessment of Cellular Proliferation in Tumors by PET Using 18F-ISO-1

R. Mach, R. Aft, R. Laforest, 2013, The Journal of Nuclear Medicine.

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

R. Advani, A. Younes, N. Bartlett, 2012, The oncologist.

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

D. Miklos, E. Jacobsen, N. Bartlett, 2017 .

Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).

D. Miklos, J. Rossi, C. Jacobson, 2017 .

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)

A. LaCasce, B. Cheson, Sin-Ho Jung, 2015, Leukemia & lymphoma.

Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens

K. Savage, H. Borghaei, E. Jacobsen, 2010 .

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

C. Gisselbrecht, S. Horwitz, N. Bartlett, 2010 .

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

R. Houot, J. Briones, C. Flowers, 2017 .

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

L. Sehn, S. Dietrich, N. Bartlett, 2022, Blood.

T-small lymphocyte disorders.

D. Longo, N. Bartlett, 1999, Seminars in hematology.

Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL).

S. Horning, N. Bartlett, A. Forero-Torres, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission

J. Armitage, J. Vose, M. Bast, 2014, Cancer.

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.

R. Advani, R. Gascoyne, D. Scott, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erratum: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (Cancer DOI: 10.1002/cncr.26510)

J. Vose, B. Cheson, K. Papadopoulos, 2012 .

RISK‐ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF a MULTICENTER PROSPECTIVE PHASE II STUDY OF DA‐EPOCH‐R

W. Wilson, J. Friedberg, K. Dunleavy, 2017 .

Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL).

D. Weisenburger, J. Vose, B. Cheson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.

K. Trinkaus, N. Bartlett, T. Fehniger, 2023, Clinical lymphoma, myeloma & leukemia.

Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

B. Christian, N. Bartlett, S. Chowdhury, 2023, Journal of Hematology & Oncology.

Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission.

J. Armitage, J. Vose, M. Bast, 2013 .

IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL

S. M. Lavezzi, G. De Nicolao, A. Howes, 2017 .

A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1

A. LaCasce, C. Jacobson, N. Bartlett, 2016 .

Modern treatment of Hodgkin lymphoma

N. Bartlett, 2008, Current opinion in hematology.

POLA‐R‐CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA

C. Haioun, N. Bartlett, C. Lee, 2017 .

Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

J. Byrd, A. LaCasce, M. Czuczman, 2015 .

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

J. Vose, J. Connors, Y. Oki, 2015, American journal of hematology.

Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease.

R. Bociek, J. Leonard, B. Cheson, 2004 .

A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)

D. Miklos, C. Gisselbrecht, C. Jacobson, 2017 .

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.

D. Podoloff, W. Erwin, N. Bartlett, 2003, Cancer biotherapy & radiopharmaceuticals.

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

J. Friedberg, J. Leonard, S. Gore, 2021, Blood.

A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA

Craig B. Davis, R. Houot, S. Patel, 2017 .

INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE

I. Lossos, S. Ansell, L. Alland, 2019, Hematological Oncology.

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

I. Flinn, N. Bartlett, C. Cheah, 2020 .

Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.

J. Leonard, Ying Yuan, N. Bartlett, 2020 .

First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.

R. Advani, J. Connors, J. Friedberg, 2022, Journal of Clinical Oncology.

The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.

S. Horning, N. Bartlett, A. Forero-Torres, 2009 .

CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma.

J. Leonard, B. Cheson, Sin-Ho Jung, 2012 .

Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.

M. Czuczman, J. Leonard, B. Cheson, 2007 .

Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.

J. Byrd, B. Cheson, D. Niedzwiecki, 2006 .

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Scott E. Smith, Allison M. Booth, J. Byrd, 2021, Blood.

Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.

E. Piccione, H. Koeppen, N. Bartlett, 2022, Journal of Clinical Oncology.

Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.

R. Advani, L. Gordon, J. Connors, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

R. Advani, J. Vose, A. LaCasce, 2016 .

Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).

J. Burke, R. Advani, K. Kolibaba, 2015 .

Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis

I. Lossos, R. Advani, J. Vose, 2011 .

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B‐cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort

I. Lossos, R. Advani, J. Vose, 2015, American journal of hematology.

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

R. Advani, K. Savage, S. Horwitz, 2021, Blood.

RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS FROM FIVE TRIALS IN PTCL, CTCL, AND B‐CELL LYMPHOMAS

S. Horwitz, N. Bartlett, M. Onsum, 2019, Hematological Oncology.

Advances in LLM: Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma.

N. Bartlett, 2012, Clinical advances in hematology & oncology : H&O.

The present: optimizing therapy--too much or too little?

N. Bartlett, 2010, Hematology. American Society of Hematology. Education Program.

Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

R. Advani, R. Gascoyne, L. Gordon, 2011 .

Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303

Scott E. Smith, L. Staudt, W. Wilson, 2016 .

High expression of nucleoside transporter protein hENT1 in Reed–Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin – A CALGB 59804 correlative study

B. Cheson, Sin-Ho Jung, J. Mackey, 2008, Leukemia & lymphoma.

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma

R. Advani, S. Horwitz, E. Jacobsen, 2022, The oncologist.

CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.

N. Bartlett, M. Wei, Sung-Soo Yoon, 2022, Journal of Clinical Oncology.

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

H. Koeppen, N. Bartlett, M. Wei, 2019, Blood.

Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma.

O. Griffith, M. Griffith, Kilannin Krysiak, 2021, Blood.

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

E. Piccione, N. Bartlett, C. Carlo-Stella, 2022, Blood.

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).

J. Leonard, B. Cheson, T. Batchelor, 2021 .

Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401)

M. Czuczman, J. Leonard, B. Cheson, 2015 .

Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia.

S. Mandrekar, A. Ruppert, N. Bartlett, 2023, Journal of geriatric oncology.

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

J. Burke, N. Bartlett, H. Prince, 2022, Blood.

HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL).

R. Advani, K. Savage, J. Radford, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

N. Bartlett, S. Neelapu, F. Locke, 2015 .

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

E. Tholouli, K. Ardeshna, K. Peggs, 2023, Blood.

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

J. Friedberg, J. Leonard, M. Shipp, 2023, Hematological Oncology.

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

P. Riedell, N. Bartlett, T. Fehniger, 2019, Blood.

A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

Sonali M. Smith, A. LaCasce, J. Leonard, 2017 .

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

J. Friedberg, J. Leonard, N. Bartlett, 2021 .

Samter's Immunologic Diseases

J. Schroeder, S. Holland, K. Austen, 2001 .

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

W. Wilson, S. Steinberg, P. Bierman, 2017 .

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

J. Friedberg, J. Leonard, B. Cheson, 2020 .

SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

Sonali M. Smith, J. Friedberg, J. Leonard, 2023, Journal of Clinical Oncology.

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.

D. Fisher, S. Horwitz, N. Bartlett, 2010 .

Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.

R. Advani, J. Vose, Sonali M. Smith, 2012 .

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

W. Wilson, J. Friedberg, J. Leonard, 2023, Cancer medicine.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

J. Byrd, R. Advani, J. Vose, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

R. Advani, K. Savage, P. Zinzani, 2020 .

Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study

R. Advani, K. Savage, N. Bartlett, 2014 .

Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study

R. Advani, K. Kolibaba, S. Ansell, 2014 .

Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.

A. Salar, N. Bartlett, C. Carlo-Stella, 2023, Journal of Clinical Oncology.

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Sonali M. Smith, J. Friedberg, J. Leonard, 2019, Blood.

CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

K. Savage, J. Radford, S. Ansell, 2021, Hematological Oncology.

BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (TRIAL IN PROGRESS)

N. Bartlett, R. Sims, W. Harwin, 2021, Hematological Oncology.

Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).

N. Bartlett, R. Sims, G. Nowakowski, 2021 .

Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma

P. Westervelt, J. Dipersio, N. Bartlett, 2020 .

KEY GENETIC AND MOLECULAR ABERRATIONS IDENTIFIED IN BOTH ADULT AND EBV‐POSITIVE BURKITT LYMPHOMA PATIENTS

L. Staudt, W. Wilson, D. Gerhard, 2021, Hematological Oncology.

Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

N. Bartlett, R. Sims, G. Nowakowski, 2020 .

Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.

R. Vij, P. Westervelt, J. Dipersio, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.

R. Advani, Y. Oki, N. Bartlett, 2012 .

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.

K. Blum, N. Bartlett, T. Fehniger, 2023, Haematologica.

A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.

K. Trinkaus, J. Dipersio, K. Blum, 2009 .

COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience

N. Bartlett, C. Farnsworth, S. Waqar, 2022, Leukemia & lymphoma.

Interdigitating dendritic reticulum cell tumor of lymph nodes: Case report with differential diagnostic considerations

L. Ylagan, N. Bartlett, M. Kraus, 2003, Diagnostic cytopathology.

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

J. Leonard, B. Cheson, H. Holte, 2006 .

Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study

B. Christian, N. Bartlett, Qiuhong Zhao, 2023, Blood Advances.

Non-Hodgkin's lymphomas.

J. Byrd, R. Advani, J. Vose, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

J. Leonard, S. Chen‐Kiang, G. Inghirami, 2016 .

M. Hallek, A. Chanan-Khan, A. Howes, 2016, The Lancet. Oncology.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Scott E. Smith, J. Connors, S. de Vos, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

R. Advani, N. Bartlett, A. Forero-Torres, 2011, Clinical Cancer Research.

Bispecific Antibodies in Lymphoma - Another Win for T Cells.

N. Bartlett, 2022, The New England journal of medicine.

Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series.

N. Bartlett, A. Forero-Torres, E. Sievers, 2010 .

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

J. Byrd, A. LaCasce, B. Cheson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.

J. Leonard, S. Chen‐Kiang, G. Inghirami, 2019, Blood.

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

J. Vose, L. Gordon, Lei Zhou, 2012 .

Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era

I. Lossos, R. Advani, J. Vose, 2013 .

A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

N. Bartlett, L. Sokol, D. Hurd, 2006 .

Postibrutinib relapse outcomes for patients with marginal zone lymphoma

F. Awan, D. Weiner, B. Christian, 2022, Blood advances.

Metabolic tumor volume predicts outcome in advanced stage follicular lymphoma patients from the Relevance trial.

I. Flinn, F. Morschhauser, O. Casasnovas, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303

Zachary L. Skidmore, L. Trani, I. Lossos, 2023, Blood advances.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Hodgkin lymphoma

C. Steidl, N. Bartlett, Antonino Carbone, 2020, Nature Reviews Disease Primers.

Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.

R. Vij, P. Westervelt, J. Dipersio, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, The New England journal of medicine.

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

L. Sehn, F. Bosch, I. Flinn, 2023, Blood advances.

Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.

Christopher A. Miller, Matthew K. Matlock, L. Trani, 2017, Blood.

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

I. Flinn, D. Miklos, C. Jacobson, 2023, Blood.

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

J. Friedberg, K. Dunleavy, N. Bartlett, 2023, Blood advances.

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.

O. Griffith, M. Griffith, B. Costello, 2018, Blood.